CARGO Therapeutics, Inc. Common Stock - Asset Resilience Ratio
CARGO Therapeutics, Inc. Common Stock (CRGX) has an Asset Resilience Ratio of 56.00% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check CRGX strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2024)
This chart shows how CARGO Therapeutics, Inc. Common Stock's Asset Resilience Ratio has changed over time. See CRGX net asset quality score to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down CARGO Therapeutics, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see CRGX market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $144.82 Million | 56.0% |
| Total Liquid Assets | $144.82 Million | 56.00% |
Asset Resilience Insights
- Very High Liquidity: CARGO Therapeutics, Inc. Common Stock maintains exceptional liquid asset reserves at 56.00% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
CARGO Therapeutics, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare CARGO Therapeutics, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 84.34% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497 |
Biotechnology | 0.02% |
|
Novavax Inc
NASDAQ:NVAX |
Biotechnology | 53.87% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for CARGO Therapeutics, Inc. Common Stock (2023–2024)
The table below shows the annual Asset Resilience Ratio data for CARGO Therapeutics, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 66.49% | $275.32 Million | $414.05 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $453.04 Million | -- |
About CARGO Therapeutics, Inc. Common Stock
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, focused on designing, engineering, and developing potentially curative cell therapies for cancer patients in the United States. The company develops CRG-023, a tri-specific CAR T product candidate which is in phase 1 that targets tumor cells with three B-cell malignancies; and allogeneic platform, a universal vector solution design… Read more